Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

Cancer Treatment Reviews

Volumn 29, Issue SUPPL. 1, 2003, Pages 21-31

  Cusack Jr , James C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bortezomib; Combination chemotherapy; Multidrug resistance; NF B; Proteasome; Resistance; Solid tumors

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CAMPTOTHECIN; CEP 1612; CISPLATIN; CURCUMIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LACTACYSTIN; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL METABOLISM; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; MYELOMA CELL; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; TUMOR XENOGRAFT; VALIDATION PROCESS;

EID: 0038189917     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00079-3     Document Type: Review

References (82)

1. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59(11): 2615-2622.
2. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5(9): 2638-2645.
3. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61(7): 3071-3076.
4. Ma MH, Parker KM, Manyak S, et al. Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-κB pathway. Blood 2001; 98(11): 437a.
5. Steiner P, Neumeier H, Lightcap ES, et al. Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. Blood 2001; 98(11): 310a.
6. Feinman R, Gangurde P, Miller S, et al. Proteasome inhibitor PS-341 inhibits constitutive NF-κB activation and bypasses the anti-apoptotic bcl-2 signal in human multiple myeloma cells. Blood 2001; 98(11): 640a.
7. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100(1): 11-17.
8. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82(1): 110-122.
9. Cusack Jr JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001; 61(9): 3535-3540.
10. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6(9): 3719-3728.
11. Neumeier H, Hoar, K, Pink, M, et al. Hypoxia increases potency of the proteasome inhibitor VELCADE (TM) (bortezomib) for injection: potential for a hypoxic cell cytotoxin in solid tumors. Presented at the EORTC-NCI-AACR Conference on Molecular Targets and Cancer Therapeutics; Frankfurt, Germany, November 19-22, 2002.
12. Pervan M, Pajonk F, Sun JR, Withers HR, McBride WH. Molecular pathways that modify tumor radiation response. Am J Clin Oncol 2001; 24(5): 481-485.
13. Russo SM, Tepper JE, Baldwin AS, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 2001; 50(1): 183-193.
14. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001; 107(3): 241-246.
15. Spencer E, Jiang J, Chen ZJ. Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP. Genes Dev 1999; 13(3): 284-294.
16. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben Neriah Y. Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1995; 92(23): 10599-10603.
17. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91(1): 3-21.
18. Ni H, Ergin M, Huang Q, et al. Analysis of expression of nuclear factor kappa B (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis. Br J Haematol 2001; 115(2): 279-286.
19. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281(5383): 1680-1683.
20. Chen C, Edelstein LC, Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x (L). Mol Cell Biol 2000; 20(8): 2687-2695.
21. Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159(5): 2212-2221.
22. Chauhan D, Pandey P, Ogata A, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997; 15(7): 837-843.
23. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95(26): 15671-15676.
24. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998; 5(12): 1062-1075.
25. Masdehors P, Merle-Beral H, Magdelenat H, Delic J. Ubiquitin-proteasome system and increased sensitivity of BCLL lymphocytes to apoptotic death activation. Leuk Lymphoma 2000; 38(5-6): 499-504.
26. Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis. Br J Cancer 1998; 77(7): 1103-1107.
27. LeBlanc R, Catley L, Hideshima T, Pien CS, Elliott PJ, Anderson KC. Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model. Blood 2001; 98(11): 774a.
28. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17(7 : 3629-3639.
29. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100(12): 2952-2960.
30. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18(51): 7389-7394.
31. Patel NM, Nozaki S, Shortle NH, et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 2000; 19(36): 4159-4169.
32. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-κB transcription factor and cancer: high expression of NF-κB- and IκB-related proteins in tumor cell lines. Biochem Pharmacol 1994; 47(1): 145-149.
33. Reuning U, Wilhelm O, Nishiguchi T, et al. Inhibition of NF-κB-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucleic Acids Res 1995; 23(19): 3887-3893.
34. Grundker C, Schulz K, Gunthert AR, Emons G. Luteinizing hormone-releasing hormone induces nuclear factor κB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 2000; 85(10): 3815-3820.
35. Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-κB is upregulated in colorectal cancer. Surgery 2001; 130(2): 363-369.
36. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5(1): 119-127.
37. Arlt A, Vorndamm J, Breitenbroich M, et al. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001; 20(7): 859-868.
38. Arlt A, Vorndamm J, Muerkoster S, et al. Autocrine production of interleukin 1β confers constitutive nuclear factor κB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002; 62(3): 910-916.
39. Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma. Oncogene 1995; 11(5): 999-1003.
40. Duffey DC, Chen Z, Dong G, et al. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59(14): 3468-3474.
41. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7(5): 1419-1428.
42. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996; 56(11): 2649-2654.
43. Chadebech P, Brichese L, Baldin V, Vidal S, Valette A. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. Biochem Biophys Res Commun 1999; 262(3): 823-827.
44. Cayrol C, Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 1998; 17(19): 2437-2444.
45. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269(5224): 682-685.
46. Salvat C, Jariel-Encontre I, Acquaviva C, Omura S, Piechaczyk M. Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts. Oncogene 1998; 17(3): 327-337.
47. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996; 10(16): 1979-1990.
48. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11(8): 957-972.
49. Sudakin V, Ganoth D, Dahan A, et al. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 1995; 6(2): 185-197.
50. Buschmann T, Fuchs SY, Lee CG, Pan ZQ, Ronai Z. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 2000; 101(7): 753-762.
51. Gorlick R, Bertino JR. Drug resistance in colon cancer. Semin Oncol 1999; 26(6): 606-611.
52. Dietrich C, Bartsch T, Schanz F, Oesch F, Wieser RJ. p53-Dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc Natl Acad Sci USA 1996; 93(20): 10815-10819.
53. Eilers M, Schirm S, Bishop JM. The MYC protein activates transcription of the α-prothymosin gene. EMBO J 1991; 10(1): 133-141.
54. Saint-Ruf C, Gerbault-Seureau M, Viegas-Pequignot E, Zafrani B, Cassingena R, Dutrillaux B. Proto-oncogene amplification and homogeneously staining regions in human breast carcinomas. Genes Chromosomes Cancer 1990; 2(1): 18-26.
55. Marcu KB, Bossone SA, Patel AJ. myc Function and regulation. Annu Rev Biochem 1992; 61: 809-860.
56. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998; 58(19): 4342-4348.
57. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999; 6(3): 279-285.
58. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327(20): 1434-1441.
59. Bergh JC. Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes. Am Rev Respir Dis 1990; 142(6 Pt 2): S20-S26.
60. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000; 60(16): 4426-4432.
61. Wang CY, Cusack Jr JC, Liu R, Baldwin ASJ. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999; 5(4): 412-417.
62. Tabata M, Tabata R, Grabowski DR, Bukowski RM, Ganapathi MK, Ganapathi R. Roles of NF-κB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma. J Biol Chem 2001; 276(11): 8029-8036.
63. Cusack JC, Liu R, Baldwin AS. NF-κB and chemoresistance: potentiation of cancer chemotherapy via inhibition of NF-κB. Drug Resist Update 1999; 2: 271-273.
64. Das KC, White CW. Activation of NF-κB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997; 272(23): 14914-14920.
65. Cusack Jr JC, Liu R, Baldwin Jr AS. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperi-dino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res 2000; 60(9): 2323-2330.
66. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277(19): 16639-16647.
67. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99(22): 14374-14379.
68. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000; 97(8): 3850-3855.
69. Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple IκB:NF-κB complexes in the resistance of cancer cells to taxol-induced apoptosis. Oncogene 2002; 21(42): 6510-6519.
70. Jones DR, Broad RM, Comeau LD, Parsons SJ, Mayo MW. Inhibition of nuclear factor κB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation. J Thorac Cardiovasc Surg 2002; 123(2): 310-317.
71. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 2001; 61(15): 5926-5932.
72. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000; 60(9): 2429-2434.
73. Mimnaugh EG, Chen HY, Davie JR, Celis JE, Neckers L. Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response. Biochemistry 1997; 36(47): 14418-14429.
74. Mimnaugh EG, Yunmbam MK, Li Q, et al. Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors: Biochem Pharmacol 2000; 60(9): 1343-1354.
75. Li QQ, Ding L, Reed E. Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells. Res Commun Mol Pathol Pharmacol 2000; 107(5-6): 387-396.
76. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000; 18(2): 109-121.
77. Wu Y, Luo H, Kanaan N, Wu J. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J Cell Biochem 2000; 76(4): 596-604.
78. Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, Draetta GF. Dual mode of degradation of Cdc25 A phosphatase. EMBO J 2002; 21(18): 4875-4884.
79. Chen F, Zhang Z, Bower J, et al. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2002; 99(4): 1990-1995.
80. Jesenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 2002; 3(2): 112-121.
81. Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 1999; 6(4): 303-313.
82. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2(4): 301-310.